Knowing that “cytokine storms” are associated with severe cases of Covid-19, Reiersen contacted her colleague Eric Lenze about doing a study together. The pair conducted a double-blind, placebo-controlled study to determine if early use of the antidepressant fluvoxamine by Covid-19 patients could reduce severe outcomes. The researchers found that clinical deterioration occurred in 0 of 80 patients in the fluvoxamine and in 6 of 72 in the placebo group.
Now, studies in at least three countries — France, the United States, and Germany — support the idea that certain antidepressants can be an effective early treatment for Covid-19.
Ahhh memories ...
